Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijcard.2013.05.072 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of efficacy of oral ivabradine for attenuation of hemodynamic response to intubation in hypertensive surgical patients: Effect on rate pressure product as an index of myocardial oxygen demand.
J Anaesthesiol Clin Pharmacol
August 2024
Department of Anesthesia, RNT Medical College, Udaipur, Rajasthan, India.
Background And Aims: An exaggerated hemodynamic response to endotracheal intubation is observed in hypertensive patients, and its attenuation proves challenging. The role of oral ivabradine, a unique heart rate-lowering drug with a favorable hemodynamic profile, is not yet studied. The aim of this study was to evaluate the effect of oral ivabradine on the attenuation of hemodynamic response to endotracheal intubation in hypertensive surgical patients assessed by rate pressure product (RPP), which is a very reliable indicator of myocardial oxygen demand.
View Article and Find Full Text PDFStructural mechanism of human HCN1 hyperpolarization-activated channel inhibition by ivabradine.
J Biol Chem
November 2024
The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China; The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China. Electronic address:
Article Synopsis
- HCN channels are essential for controlling how neurons behave, and inhibiting HCN1 could help in treating neurological issues, but the details of how this inhibition happens weren't clear.
- Researchers used cryo-electron microscopy to show how the drug ivabradine binds to a specific site on the human HCN1 channel, revealing new structural details of this interaction.
- Additionally, they identified two existing FDA-approved drugs that can also target this binding site, paving the way for new treatments aimed at regulating HCN1 activity in neurological disorders.
Beyond quadruple therapy: the potential roles for ivabradine, vericiguat, and omecamtiv mecarbil in the therapeutic armamentarium.
Heart Fail Rev
September 2024
Duke Clinical Research Institute, 300 W Morgan St, Durham, NC, 27701, USA.
Quadruple therapy is effective for patients with heart failure with reduced ejection fraction, providing significant clinical benefits, including reduced mortality. Clinicians are now in an era focused on how to initiate and titrate quadrable therapy in the early phase of the disease trajectory, including during heart failure hospitalization. However, patients with heart failure with reduced ejection fraction still face a significant "residual risk" of mortality and heart failure hospitalization.
View Article and Find Full Text PDFEvaluating the role of ivabradine in acute decompensated heart failure: A systematic review and meta-analysis.
Curr Probl Cardiol
August 2024
Department of Internal Medicine, Seth GS Medical College and KEM Hospital, Acharya Donde Marg, Parel, Mumbai 400012, India. Electronic address:
Background: Acute decompensated heart failure (ADHF) presents a significant global health challenge, with high morbidity, mortality, and healthcare costs. The current therapeutic options for ADHF are limited. Ivabradine, a selective inhibitor of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, has emerged as a potential therapy for ADHF by reducing the heart rate (HR) without negatively affecting myocardial contractility.
View Article and Find Full Text PDFScreening effects of HCN channel blockers on sleep/wake behavior in zebrafish.
Front Neurosci
March 2024
Vanda Pharmaceuticals Inc., Pennsylvania, Washington, DC, United States.
Hyperpolarization-activated cyclic nucleotide-gated (HCN) ion channels generate electrical rhythmicity in various tissues although primarily heart, retina and brain. The HCN channel blocker compound, Ivabradine (Corlanor), is approved by the US Food and Drug Administration (FDA) as a medication to lower heart rate by blocking hyperpolarization activated inward current in the sinoatrial node. In addition, a growing body of evidence suggests a role for HCN channels in regulation of sleep/wake behavior.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!